90 result(s)
Home Medical Affairs
Get access to the latest news and research in medical affairs with this comprehensive portal. Stay up-to-date with the latest clinical trials, studies, and developments in the medical field. Explore a variety of resources to enhance your knowledge and stay informed.
Contact Us Confirmation
Solicite la visita de uno de nuestros delegados de GSK- Confirmación
GSK Medical Affairs - Contact
Contacte con el centro de información, solicite la visita de un delegado o el contacto por el departamento médico, Notifique de una sospecha de reacción adversa
Clinical Remission in Asthma
A collection of materials addressing Clinical Remission in asthma which is an ambitious but attainable treatment goal for patients with asthma irrespective of disease severity and treatment history
CAPTAIN Study main results video
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy in asthma using a precision medicine approach. In this video, Professor Ian Pavord presents the main results from the CAPTAIN study
AAAAI 2024 CAPTAIN study post-hoc Clinical Remission oral presentation (key take aways video)
Video recording of Prof. Oppenheimer presenting key takeaways from the CAPTAIN clinical remission post hoc analysis results from AAAAI 2024
Audio for the FULFIL Study Post Hoc Analysis Poster P630 at ATS 2024
Audio of Prof. David Singh presenting the FULFIL Study Post Hoc Analysis at ATS 2024
CAPTAIN Study sub-group analysis video
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy in asthma using a precision medicine approach. In this video, Professor Ian Pavord presents a sub-group analysis from the CAPTAIN study exploring the impact of type 2 biomarker status on outcomes.
What is Clinical Remission concept video
Video recording of Prof. Oppenheimer providing an overview of clinical remission in asthma
Audio for the FULFIL Study Post Hoc Analysis Poster P630 at ATS 2024
Audio of Prof. David Singh presenting the FULFIL Study Post Hoc Analysis at ATS 2024
GAA May Webinar_ Lavoie Pre-recorded video
GSK-GAA Webinar 2024: Optimising evidence through a patient-centred approach
GAA May Webinar_ Panel Pre-recorded video
GSK-GAA Webinar 2024: Panel Discussion
MoD video (localisable version)
Short video summarising the IL-5 biology and recent evidence surrounding this science, as well as the cells impacted directly and indirectly by the IL-5 pathway.
uUTI Mechanism of Disease Video
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy in asthma using a precision medicine approach. In this video, Professor Ian Pavord presents the main results from the CAPTAIN study
GAA May Webinar_ Yorgancıoğlu Pre-recorded video
GSK-GAA Webinar 2024: Personalized Asthma Care in the Clinic - Applying the latest evidence
NMA in Triple Therapy summary
For FF/UMEC/VI, the NMA suggest favourable efficacy compared with other single-inhaler triple therapies.
CAPTAIN Study Clinical Remission Poster: ATS 2024
Poster from ATS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
NMA in Triple Therapy: Class comparison data in COPD
FF/UMEC/VI versus triple and dual bronchodilator therapies
The EMAX trial
Asthma is a heterogeneous disease and its management is multifactorial; many patients often remained uncontrolled despite treatment. HCPs have a critial role in identifying and managing patients who are not adequately controlled, which involves: -Regular discussions with patients -Recognition of symptoms and exacerbation risks -Continuous assessment of treatment -Reassessment of treatment and follow-up
Inhaled molecules for COPD treatment
How does molecule pharmacology correlate with clinical efficacy and safety? Pharmacological properties of inhaled respiratory molecules are critical to ensure the best possible clinical outcomes.
Network Meta-analysis (NMA) introduction for Triple Therapy
Comparing efficacy of triple therapies among patients with COPD. Multiple RCTs have demonstrated the benefit of triple over dual inhaled therapy in improving lung function and reducing the risk of exacerbation for patients with COPD
Inhalers in Respiratory Medicine > Unmet Need
In this section the symptom burden and unmet needs of patients with COPD are discussed, as well as the importance of correct inhaler technique and the impact of multiple inhaler therapy.
Inhalers in Respiratory Medicine >Patient Benefits
What are the key considerations affecting inhaler choice, from a patient and physician perspective?
Inhalers in Respiratory Medicine >Clinical Efficacy
Clinical efficacy of inhaled therapy delivered via the Ellipta inhaler. As well as ease of use, and fewer patients making an error with their inhaler, treatments are needed that show clinical efficacy.
RWE interactive map 2024
An interactive map displaying RWE studies in asthma, CRSwNP, EGPA, COPD and HES
EAACI 2024: Medical booth IL-5 digital infographic
Interactive pdf explaining the impact of IL-5 beyond eosinophils on cells. including its role in a variety of pathophysiological processes
AAAAI 2024 CAPTAIN study post-hoc Clinical Remission oral presentation (full video)
Video recording of Prof. Oppenheimer presenting key takeaways from the CAPTAIN clinical remission post hoc analysis results from AAAAI 2024
CAPTAIN Study Clinical Remission Poster: ATS 2024
Poster from ATS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
Han, M.K., Vanfleteren, L.E.G.W., Kolterer, S. et al. Striving for Stability in Patients with COPD: A New Way Forward?. Adv Ther (2024)
ERS 2024 supplemental symposium report
Medical COPD portfolio symposium summary video_ERS 2024
Short video with the faculty, summarising the key takeaways of the symposium.
Talking Head Video
Short Talking Head Videos outlining the unmet need in Refractory Chronic Cough and the importance of early recognition
Characteristics of patients meeting the components of clinical remission: CAPTAIN post hoc analysis.
Poster PA1197 from ERS 2024 presenting post hoc analysis of clinical remission from the CAPTAIN study.
CAPTAIN Clinical Remission ERS baseline; audio for poster PA1198
Audio to support poster PA1197 from ERS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
CAPTAIN Clinical Remission ERS lung function; audio for poster PA1199
Audio to support poster PA1197 from ERS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
Characteristics of severe eosinophilic asthma
Severe asthma with eosinophilic phenotype is a distinct phenotype of severe asthma. This phenotype is characterized by airway inflammation, increased blood/sputum eosinophil (EOS) concentrations, poor asthma control, and increased rate of exacerbations.
Impact of varying health status thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis.
Halpin MGD, et al. By demonstrating the effect of inhaled therapies on measures of health status (SGRQ and CAT) according to different thresholds, it may be possible to better assess disease stability in clinical practice. Disease stability should be considered an ambitious, practical and realisable treatment goal for patients with COPD, with the potential to guide patient management. Poster PA1173
Impact of varying lung function thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis.
Halpin MGD, et al. By demonstrating the effect of inhaled therapies on different lung function thresholds, it may be possible to better assess disease stability in clinical practice. Disease stability should be considered an ambitious, practical and realisable treatment goal for patients with COPD, with the potential to guide patient management. Presentation OA4653
Assessment of the components of clinical remission with moderate–severe asthma after 24–52 weeks of treatment: CAPTAIN post hoc analysis
Poster PA1198 from ERS 2024 presenting post hoc analysis of clinical remission from the CAPTAIN study.
Towards disease stability in COPD management: patient perspectives
Brooke M, et al. Patient advocacy advisors highlight disease stability as a desirable treatment goal for COPD, driven by patient aspirations and clinical characteristics. Personalisation of treatment strategies and patient care underpins the achievement and maintenance of disease stability resulting in improvements to the quality of life for patients living with COPD. Poster PA1171
Impact of varying lung function threshold on clinical remission in asthma with FF/UMEC/VI: CAPTAIN post hoc analysis.
Poster PA1199 from ERS 2024 presenting post hoc analysis of clinical remission from the CAPTAIN study.
Real-world assessment of clinical remission in asthma with biologics Howarth P, et al. Poster PA2182
ERS Poster
ERS 2024 SOOTHE Study Poster
Smith JA, et al. Prior and concomitant medication use in patients with refractory chronic cough: post-hoc analysis of SOOTHE. ERS 2024. Poster No. PA319
CAPTAIN Clinical Remission ERS Poster Mod-Sev Audio for poster PA 1197
Audio to support poster PA1197 from ERS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
Expert video describing disease stability
Video by Prof Dave Singh and Prof MeiLan Han describing disease stability and what it might mean for patients.
Refractory Chronic Cough Patient Story video
Short Video of RCC patient sharing the burden of this disease
RCC Mechanism of Disease Loop Video
Short video looking at the pathophysiology of refractory chronic cough
Load more
Thank you for your query. We're sorry, but we don't find information about this topic:
Here are some steps that you can take to improve the accuracy of your search:
- Check the spelling of your search.
- Try a different wording.
- Reset or review the filters applied (if filters were used to perform this search).
- Check the accuracy of your search terms.
- Try using multiple keywords to narrow down your search.
- Try using synonyms or related words to broaden your search.
